Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

• 主要な著者: Liu D (著者), Offin M (著者), Harnicar S (著者), Li BT (著者), Drilon A (著者)
• フォーマット: 図書
• 出版事項: Dove Medical Press, 2018-07-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell...